Member Info for L2analyst

Theres too much buying orders queuing up

16p to buy

Anything could happen here, takeover or partnership, question is do you want to be in or out potential is huge

29p for 689,610 shares very nice

Added 10k shares only at 26.50p if someones happy to pay 29p then 26.50p is bargain

They still hold massive 14.3 per cent

Yesterday buy at 29p surprised to see it down!

I'm amazed this share is not moving like bhr

Somthing is brewing, for 15k shares they want me to pay 18p!!

That is cheap aisc

la India open pit hosts a Probable Mineral Reserve of 6.9 million tonnes ("Mt") at 3.01 g/t gold for 675,000 oz gold with all-in-sustaining-cash costs of US$690 per oz gold.

Theres growing concern with South African varient, this covid is mutating, current vaccines are not effective

Classic pull back now watch it go back up

Something is triggering the buys

Mm upto silly games, actual price to buy is 11.20p

Ig quoting 28.40p to buy

28.10p to buy now i think 30p plus today

Just imagine if one of those big pharmaceutical companies do a partnership

Thanks scousemark, l2 looking very nice for a breakout

COVID-19 vaccine candidate selected

Fri, 18th Dec 2020 07:00

RNS Number : 0847J

Scancell Holdings Plc

18 December 2020

 

18 December 2020

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell announces selection of COVID-19 vaccine candidate, SN14

 

SN14 offers several potential advantages over currently approved and late-stage COVID-19 vaccines

 

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies is pleased to announce that they have selected their COVID-19 vaccine candidate, SN14, for further development and clinical trials. SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain (RBD) of the spike (S) protein, and is based on a modification of Scancell's ImmunoBody® DNA vaccine technology.

 

Fifteen vaccine candidates containing different S and N components combined with a variety of targeting technologies were evaluated for the best T cell and antibody responses. SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins. SN14 also incorporates Scancell's AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.

 

SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:

· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.

· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.

· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.

· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using relatively simple processe

11.70p to buy now